SVB Leerink Comments on Athenex, Inc.’s FY2021 Earnings (NASDAQ:ATNX)

Athenex, Inc. (NASDAQ:ATNX) – SVB Leerink raised their FY2021 earnings per share (EPS) estimates for Athenex in a research report issued to clients and investors on Monday, October 11th. SVB Leerink analyst J. Chang now expects that the company will post earnings per share of ($0.68) for the year, up from their previous estimate of ($1.13). SVB Leerink currently has a “Market Perform” rating and a $4.00 price target on the stock. SVB Leerink also issued estimates for Athenex’s Q4 2021 earnings at ($0.06) EPS and FY2022 earnings at ($0.13) EPS.

Other equities analysts have also recently issued reports about the company. Oppenheimer reiterated a “hold” rating on shares of Athenex in a report on Tuesday, July 6th. Needham & Company LLC reiterated a “hold” rating on shares of Athenex in a report on Tuesday, July 6th. Royal Bank of Canada cut their price target on Athenex from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Zacks Investment Research raised Athenex from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Wednesday, October 6th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Athenex presently has a consensus rating of “Hold” and a consensus target price of $8.91.

Shares of ATNX opened at $2.71 on Thursday. Athenex has a 52-week low of $2.50 and a 52-week high of $15.00. The company has a market capitalization of $296.23 million, a PE ratio of -1.73 and a beta of 0.68. The stock has a fifty day simple moving average of $3.31 and a two-hundred day simple moving average of $4.01. The company has a quick ratio of 2.91, a current ratio of 3.39 and a debt-to-equity ratio of 0.86.

Athenex (NASDAQ:ATNX) last issued its earnings results on Wednesday, August 4th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. Athenex had a negative return on equity of 84.67% and a negative net margin of 121.58%. The business had revenue of $21.92 million during the quarter, compared to the consensus estimate of $22.07 million.

A number of institutional investors have recently added to or reduced their stakes in the stock. First Trust Advisors LP purchased a new stake in shares of Athenex in the first quarter worth about $1,054,000. Swiss National Bank raised its stake in Athenex by 2.6% during the first quarter. Swiss National Bank now owns 128,000 shares of the company’s stock valued at $550,000 after buying an additional 3,300 shares in the last quarter. BlackRock Inc. raised its stake in Athenex by 2.1% during the first quarter. BlackRock Inc. now owns 6,248,848 shares of the company’s stock valued at $26,871,000 after buying an additional 128,608 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Athenex by 7.7% during the 1st quarter. New York State Common Retirement Fund now owns 60,323 shares of the company’s stock worth $259,000 after purchasing an additional 4,300 shares during the period. Finally, UBS Group AG raised its position in shares of Athenex by 1,087.2% during the 1st quarter. UBS Group AG now owns 724,874 shares of the company’s stock worth $3,117,000 after purchasing an additional 663,814 shares during the period. Hedge funds and other institutional investors own 46.24% of the company’s stock.

In other Athenex news, Director Jinn Wu purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, October 1st. The shares were purchased at an average cost of $2.67 per share, for a total transaction of $26,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 14.19% of the stock is owned by insiders.

About Athenex

Athenex, Inc is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs.

See Also: Penny Stocks, Risk and Reward Factors

Earnings History and Estimates for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.